Cetuximab plus chemotherapy in patients with advanced non-small-cell lung cancer (FLEX): an open-label randomised phase III trialRobert Pirker, U. Gatzemeier, Maciej Krzakowski et al.|The Lancet|2009Cited by 1.4k
Nivolumab Versus Docetaxel in Previously Treated Patients With Advanced Non–Small-Cell Lung Cancer: Two-Year Outcomes From Two Randomized, Open-Label, Phase III Trials (CheckMate 017 and CheckMate 057)Leora Horn, Wilfried Eberhardt|Journal of Clinical Oncology|2017Cited by 872
EGFR expression as a predictor of survival for first-line chemotherapy plus cetuximab in patients with advanced non-small-cell lung cancer: analysis of data from the phase 3 FLEX studyRobert Pirker, Kenneth J. O’Byrne, Jose R. Pereira et al.|The Lancet Oncology|2011Cited by 574
Brain metastases in ALK-positive NSCLC - time to adjust current treatment algorithmsFrank Griesinger, Wilfried Eberhardt|Oncotarget|2018Cited by 51